Between 2020 and 2024, there were no recorded deaths
Two decades after wealthy nations began vaccinating adolescent girls against human papillomavirus, England's data has arrived with quiet force: among women who received the HPV vaccine in their school years, cervical cancer deaths fell by 80 percent, and then, between 2020 and 2024, to zero. Published in The Lancet by researchers at Queen Mary University of London, this finding places a familiar public health tool in a new light — not merely as disease prevention, but as a demonstrable shield against death itself. The achievement belongs to sustained commitment, and its limits remind us that a medical triumph confined to wealthy nations is, in the fullest sense, only half a triumph.
- A virus so common it infects most sexually active people worldwide has, for vaccinated young women in England, lost its power to kill — a shift from statistical probability to recorded zero deaths over five years.
- Researchers caution that population-level data cannot fully isolate the vaccine's role from parallel gains in screening programs and the quiet protection of herd immunity among unvaccinated peers.
- The vaccinated cohort is still young, and cervical cancer grows more dangerous with age — the true test of these gains will unfold over the coming decades as these women move through their forties and fifties.
- England's success rests on a specific architecture — high sustained coverage paired with robust screening infrastructure — a combination most low-income countries, where HPV burden is greatest, do not yet have.
- The WHO's goal of global cervical cancer elimination now has a proof of concept, but proof of concept is not policy, and the distance between England's outcome and the world's most vulnerable populations remains vast and urgent.
When England launched its school-based HPV vaccination program in the mid-2000s, the ambition was clear but the evidence was still forming. Two decades later, researchers at Queen Mary University of London have published findings in The Lancet that mark a turning point: among women vaccinated between ages 12 and 18, cervical cancer deaths dropped 80 percent in the years 2015 to 2019, and from 2020 to 2024, no deaths were recorded at all. It is one of the first rigorous studies to measure the vaccine's effect on mortality rather than disease incidence alone.
The biology behind the result is well established. HPV is the world's most common sexually transmitted infection, with over 200 known strains. Most infections resolve without consequence, but certain high-risk types persist and drive nearly all cervical cancer diagnoses. England's vaccination program achieved a 90 percent reduction in HPV infections among young people — a figure that moved the country meaningfully toward its goal of eliminating cervical cancer as a public health problem by 2040.
Experts urge measured interpretation. Dr. Allison Portnoy of Boston University notes in a companion commentary that the study works at the population level, making it difficult to isolate the vaccine's contribution from concurrent improvements in screening and the protective effects of herd immunity. Longer follow-up will also be essential — the vaccinated cohort is still young, and cervical cancer risk rises with age, meaning the durability of these gains remains an open question.
What the data does confirm, Portnoy argues, is what sustained high coverage paired with strong screening infrastructure can achieve. The harder challenge is global. HPV rates are highest in low-income countries, where vaccination programs are sparse and screening is often out of reach. England's experience offers a model and a proof of concept — but translating that into equitable outcomes will require deliberate, sustained investment in the places where the burden of this disease remains most severe.
In the mid-2000s, when wealthy nations began vaccinating adolescent girls against human papillomavirus, few could have predicted what the numbers would eventually show. Two decades later, researchers at Queen Mary University of London have documented something striking: among women in England who received the HPV vaccine between ages 12 and 18, cervical cancer deaths fell by 80 percent in the years 2015 through 2019. Between 2020 and 2024, there were no recorded deaths from cervical cancer in this vaccinated cohort at all—a finding published in The Lancet that marks one of the first rigorous examinations of the vaccine's impact on mortality rather than just disease incidence.
The virus itself is nearly ubiquitous. The World Health Organization identifies HPV as the most common sexually transmitted infection globally, with more than 200 known types circulating. Most people who contract it experience no symptoms and clear the infection naturally. But certain high-risk strains persist, and these strains are responsible for nearly all cervical cancer diagnoses. When England's school-based vaccination program launched, it targeted adolescent girls with a straightforward goal: prevent cervical cancer before exposure to the virus. The strategy worked. The program achieved a 90 percent reduction in HPV infections among young people, moving the country substantially closer to its stated objective of eliminating cervical cancer as a public health problem by 2040.
Yet the researchers and outside experts urge caution in drawing simple conclusions. Dr. Allison Portnoy, an assistant professor of global health at Boston University, notes in a companion commentary that while the study connects mortality data to vaccination coverage, it operates at the population level rather than tracking individual women. Other forces were at work simultaneously. Cervical cancer screening programs expanded and improved during the same period. Vaccinated individuals are less likely to transmit HPV to unvaccinated people, creating what epidemiologists call herd immunity. Disentangling the vaccine's specific contribution from these overlapping interventions requires more granular data than population-level trends alone can provide.
Still, the direction is unmistakable. The women who benefited most from this vaccination campaign are still young—in their twenties and early thirties. Cervical cancer mortality typically rises with age, and different HPV genotypes may affect risk differently across the lifespan. Longer follow-up will be essential to understand whether these gains hold as vaccinated cohorts age into their forties, fifties, and beyond, when the disease becomes more common. The research community will be watching closely.
What the England data does demonstrate, Portnoy argues, is what becomes possible when a country sustains high vaccination coverage over time and pairs it with robust screening infrastructure. The challenge now is global. HPV infection rates are highest in low-income countries, where vaccination programs remain sparse and screening is often unavailable. Without deliberate effort to expand access, the gap between wealthy nations and poorer ones will only widen. The World Health Organization has set an ambitious target: cervical cancer elimination globally. England's experience suggests it is achievable. But realizing that vision will require sustained investment in vaccination, screening, and treatment capacity in the places where the burden of disease remains heaviest—and where the need is most urgent.
Citações Notáveis
The study makes an important contribution to the literature on the population-level impact of HPV vaccination by connecting mortality data and HPV vaccine coverage data, but these are indeed population-level rather than individual-level data.— Dr. Allison Portnoy, Boston University School of Public Health
Realizing similar gains globally will require intentional implementation and delivery strategies to mitigate inequalities in cervical cancer burden.— Dr. Allison Portnoy
A Conversa do Hearth Outra perspectiva sobre a história
When you say there were zero deaths between 2020 and 2024, does that mean the vaccine is perfect?
It means something remarkable happened in that specific group—women vaccinated as teenagers in England. But the researchers are careful not to claim the vaccine alone did this. Screening got better at the same time. People who were vaccinated are less likely to spread the virus to others. All of that matters.
So we can't actually prove the vaccine caused the decline?
We can prove it prevents the precancerous cells that lead to cervical cancer. That's been established. What's harder to prove is how much of this particular mortality drop came from the vaccine versus screening improvements or herd immunity. The data is population-level, not individual-level.
Why does that distinction matter?
Because it's the difference between knowing a vaccine works and knowing exactly how much credit it deserves in a real-world setting where multiple things are happening at once. Both are valuable, but they answer different questions.
What happens next?
These women are still young. Cervical cancer usually kills people in their forties and fifties. We need to follow them for decades to see if the protection holds. And we need to figure out how to get this same protection to women in countries where HPV rates are highest but vaccination programs barely exist.
Is that a realistic goal?
England shows it's possible if you have the resources and the will. The question is whether the world has both.